GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » Gross Profit

Extrawell Pharmaceutical Holdings (HKSE:00858) Gross Profit : HK$28.78 Mil (TTM As of Mar. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings Gross Profit?

Extrawell Pharmaceutical Holdings's gross profit for the six months ended in Mar. 2024 was HK$13.89 Mil. Extrawell Pharmaceutical Holdings's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was HK$28.78 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Extrawell Pharmaceutical Holdings's gross profit for the six months ended in Mar. 2024 was HK$13.89 Mil. Extrawell Pharmaceutical Holdings's Revenue for the six months ended in Mar. 2024 was HK$28.96 Mil. Therefore, Extrawell Pharmaceutical Holdings's Gross Margin % for the quarter that ended in Mar. 2024 was 47.96%.

Extrawell Pharmaceutical Holdings had a gross margin of 47.96% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Extrawell Pharmaceutical Holdings was 55.59%. The lowest was 39.63%. And the median was 48.89%.

Warning Sign:

Extrawell Pharmaceutical Holdings Ltd gross margin has been in long-term decline. The average rate of decline per year is -4.2%.


Extrawell Pharmaceutical Holdings Gross Profit Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings Gross Profit Chart

Extrawell Pharmaceutical Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.92 42.57 37.56 31.14 28.78

Extrawell Pharmaceutical Holdings Semi-Annual Data
Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.75 13.53 17.61 14.89 13.89

Competitive Comparison of Extrawell Pharmaceutical Holdings's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Extrawell Pharmaceutical Holdings's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where Extrawell Pharmaceutical Holdings's Gross Profit falls into.



Extrawell Pharmaceutical Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Extrawell Pharmaceutical Holdings's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as

Gross Profit (A: Mar. 2024 )=Revenue - Cost of Goods Sold
=59.098 - 30.319
=28.78

Extrawell Pharmaceutical Holdings's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=28.957 - 15.069
=13.89

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$28.78 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Extrawell Pharmaceutical Holdings's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=13.89 / 28.957
=47.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Extrawell Pharmaceutical Holdings  (HKSE:00858) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Extrawell Pharmaceutical Holdings had a gross margin of 47.96% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Extrawell Pharmaceutical Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Extrawell Pharmaceutical Holdings Business Description

Traded in Other Exchanges
N/A
Address
979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.
Executives
Mao Yumin 2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited 2201 Interest of corporation controlled by you
Ease Gold Investments Limited 2201 Interest of corporation controlled by you
Jnj Investments Ltd 2201 Interest of corporation controlled by you
United Gene Group Ltd 2201 Interest of corporation controlled by you
United Gene Holdings Limited 2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited 2101 Beneficial owner
Xie Yi 2201 Interest of corporation controlled by you
Huang Zhenping 2101 Beneficial owner
United Gene Industry Group Limited 2101 Beneficial owner
Chen Xuhua 2202 Interest of your spouse
Cheng Yong 2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings Headlines

No Headlines